Boston Scientific Corp Files 8-K for Regulation FD Disclosure

Ticker: BSX · Form: 8-K · Filed: 2024-11-07T00:00:00.000Z

Sentiment: neutral

Topics: disclosure, regulation-fd

Related Tickers: BSX

TL;DR

BSX filed an 8-K for a Reg FD disclosure, no new material info detailed.

AI Summary

On November 7, 2024, Boston Scientific Corporation (BSX) filed an 8-K to report a Regulation FD Disclosure. The filing does not contain specific financial figures or new material events beyond the reporting of the disclosure itself.

Why It Matters

This filing indicates Boston Scientific is making a public disclosure under Regulation FD, ensuring all investors receive the same material information simultaneously.

Risk Assessment

Risk Level: low — The filing is a standard procedural disclosure and does not contain information that would immediately impact the company's risk profile.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report a Regulation FD Disclosure made by Boston Scientific Corporation on November 7, 2024.

What specific material information is disclosed in this filing?

This filing itself does not detail the specific material information being disclosed under Regulation FD; it only serves as notification of the disclosure.

When was this 8-K filed?

This 8-K was filed on November 7, 2024.

What is the company's principal business address?

The company's principal business address is 300 Boston Scientific Way, Marlborough, Massachusetts 01752-1234.

Under which section of the Securities Exchange Act is this report filed?

This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

From the Filing

0000885725-24-000075.txt : 20241107 0000885725-24-000075.hdr.sgml : 20241107 20241107070047 ACCESSION NUMBER: 0000885725-24-000075 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20241107 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20241107 DATE AS OF CHANGE: 20241107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 241433064 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 8-K 1 bsx-20241107.htm 8-K bsx-20241107 0000885725 false 0000885725 2024-11-07 2024-11-07 0000885725 us-gaap:CommonStockMember 2024-11-07 2024-11-07 0000885725 bsx:SeniorNotedue2027Member 2024-11-07 2024-11-07 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________ FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 _____________________________________________________________________ Date of Report (Date of earliest event reported): November 7, 2024 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)      300 Boston Scientific Way , Marlborough , Massachusetts                  01752-1234     (Address of principal executive offices)                           (Zip Code) ( 508 ) 683-4000 (Registrant's telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.01 par value per share BSX New York Stock Exchange 0.625% Senior Notes due 2027 BSX27 New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company    ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐ Item 7.01 Regulation FD Disclosure. On November 7, 2024, Boston Scientific Corporation (the “Company”) announced that it is resuming the AVANT GUARD clinical trial studying a new population of drug-naïve patients with persistent atrial fibrillation. The decision to resume enrollments in the trial was made following an a

View on Read The Filing